WALTHAM, Mass.--(BUSINESS WIRE)--Glytec, the only provider of insulin management software across the continuum of care, announced today that healthcare providers from five separate health systems will present studies on the transformative effects of implementing its eGlycemic Management System (eGMS) during the 2020 Diabetes Technology Society (DTS) Virtual Hospital Poster Session.
Attendees of this online session taking place June 18 at 3 p.m. EDT will hear findings from clinical research into the use of computer-guided insulin dosing and its impact on glycemic management in acute care settings.
Results of these studies include reduced hyperglycemic and hypoglycemic events, a decreased financial burden on patients and health systems, and well-documented efficacy of large-scale eGMS utilization.
The poster presentations involving Glytec eGMS include:
The 2020 DTS Virtual Hospital Poster Session is a continuation of April’s DTS Virtual Hospital Meeting, which included a three-part session dedicated to computer-guided insulin dosing and highlighted the successful implementation of Glytec eGMS in the AdventHealth and CHI Franciscan health systems. The Virtual Hospital Poster Session will feature 10 presentations in total and registration is free. In addition, attendees are eligible for one unit of continuing education credit. For more information and to register visit www.diabetestechnology.org/hdm/poster-session.shtml. Presentation videos and posters will also be available at www.GlytecSystems.com/evidence at the conclusion of the event.
Glytec is the insulin management software company for healthcare providers focused on improving the quality and cost of care. Its FDA-cleared titration software and proprietary algorithms power the only solution capable of delivering personalized diabetes treatment recommendations across the continuum of care, from hospital to home. With ongoing support from its team of doctors, nurses and technologists headquartered outside of Boston, Glytec improves outcomes and controls costs for the large population of patients requiring insulin treatment – including those with and without a diagnosis of diabetes. For more information, follow Glytec on Twitter (@Glytec) or LinkedIn, or visit www.GlytecSystems.com.